Company profile
UK company 03237549, incorporated on 13 August 1996.
Cyclacel Pharmaceuticals, Inc. - Harnessing the cell cycle to treat cancer and other serious diseases
Harnessing the cell cycle to treat cancer and other serious diseases About Cyclacel As a clinical-stage, biopharmaceutical company, we develop innovative ca ...
Company number 03237549
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Dec 2013 to 30 Nov 2016
Cyclacel has developed a clinical candidate NCE with characteristics enabling the targeting of a previously unexploited mechanism for treatment of oesophageal cancer (OEC), an orphan disease with a high unmet need. This potent and selective PLK1 kinase inhibitor has a strong preclinical rationale for use as a stratified medicine for OEC and other solid tu...
1 Jan 2013 to 31 Dec 2015
Cyclacel has developed a novel clinical candidate NCE affecting previously unexplored pathways for treatment of acute leukaemia. The compound has a strong rationale for use as a stratified medicine for adult, infant and paediatric indications which have a high unmet medical need. The drug development project encompasses preclinical validation of marker as...
